Literature DB >> 2704029

Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.

R Bäckström1, E Honkanen, A Pippuri, P Kairisalo, J Pystynen, K Heinola, E Nissinen, I B Linden, P T Männistö, S Kaakkola.   

Abstract

A series of disubstituted catechol derivatives was synthesized and tested as potential COMT inhibitors. The most active compounds were more than 1000 times more potent (IC50 = 3-6 nM) in vitro than the known COMT inhibitor, 3',4'-dihydroxy-2-methylpropiophenone (U 0521, IC50 = 6000 nM). The new compounds were also highly selective COMT inhibitors with no activity against other essential enzymes involved in the synthesis and metabolism of catecholamines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2704029     DOI: 10.1021/jm00124a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.

Authors:  T Lotta; J Taskinen; R Bäckström; E Nissinen
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

2.  Inhibitors of catechol-O-methyltransferase sensitize mice to pain.

Authors:  O Kambur; R Talka; O B Ansah; V K Kontinen; A Pertovaara; E Kalso; P T Männistö
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 4.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

7.  The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.

Authors:  S Sundberg; M Scheinin; P Ojala-Karlsson; J Akkila; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  (E)-Ethyl 2-cyano-3-(3,4-dihydr-oxy-5-nitro-phen-yl)acrylate.

Authors:  Shi-Jie Zhang; Xian-Ming Zheng; Wei-Xiao Hu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-09-05

Review 9.  Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.

Authors:  Zhiguo Ma; Hongming Liu; Baojian Wu
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

10.  Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.

Authors:  P T Männistö; P Tuomainen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.